Endomines shortens silent period to 21 days ahead of financial reporting releases
Bitget2026/10/06 12:48Endomines Finland’s board has decided to shorten the company’s silent period to 21 days from 30 days ahead of interim reports, half-year reports, and financial statement releases. The change takes effect immediately. The board also ordered updates to the company’s disclosure policy and related investor communications guidelines to reflect the new practice. The MAR 30-day closed period for managerial insiders remains unchanged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endomines Finland Oyj published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Endomines Finland’s board has decided to shorten the company’s silent period to 21 days from 30 days ahead of interim reports, half-year reports, and financial statement releases.
- The change takes effect immediately.
- The board also ordered updates to the company’s disclosure policy and related investor communications guidelines to reflect the new practice.
- The MAR 30-day closed period for managerial insiders remains unchanged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.